Sana Biotechnology (SANA) Change in Accured Expenses (2020 - 2026)

Sana Biotechnology has disclosed Change in Accured Expenses across 7 years of filings, most recently posting -$7.1 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$7.1 million, up 20.23% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.9 million (up 60.63% YoY), and the FY2025 annual result was -$4.7 million, up 43.54% from the prior year.
• Change in Accured Expenses came in at -$7.1 million for Q1 2026 at Sana Biotechnology, down from $5.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.9 million in Q3 2022 to a low of -$10.3 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $167000.0 (2023), against an average of -$637000.0.
• Across the five-year window, Change in Accured Expenses sank 1913.17% in 2024 and surged 304.56% in 2025, its largest moves.
• Sana Biotechnology's Change in Accured Expenses stood at $2.1 million in 2022, then plunged by 91.96% to $167000.0 in 2023, then tumbled by 1913.17% to -$3.0 million in 2024, then surged by 290.13% to $5.8 million in 2025, then slumped by 223.22% to -$7.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$7.1 million (Q1 2026), $5.8 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.